| 5.35 -0.05 (-0.93%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.19 | 1-year : | 8.4 |
| Resists | First : | 6.15 | Second : | 7.19 |
| Pivot price | 5.18  |
|||
| Supports | First : | 3.92 | Second : | 2.54 |
| MAs | MA(5) : | 5.35  |
MA(20) : | 5.12 |
| MA(100) : | 3.26 |
MA(250) : | 3.14 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 58.8 |
D(3) : | 61.8 |
| RSI | RSI(14): 61.3 |
|||
| 52-week | High : | 6.15 | Low : | 1.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CATX ] has closed below upper band by 37.5%. Bollinger Bands are 13.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.48 - 5.5 | 5.5 - 5.53 |
| Low: | 4.99 - 5.02 | 5.02 - 5.05 |
| Close: | 5.3 - 5.35 | 5.35 - 5.4 |
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Sat, 28 Feb 2026
CATX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Wed, 25 Feb 2026
CATX SEC Filings - Perspective Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Mon, 23 Feb 2026
349,323 Shares in Perspective Therapeutics, Inc. $CATX Purchased by Patient Square Capital LP - MarketBeat
Sun, 22 Feb 2026
CATX - Perspective Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Thu, 19 Feb 2026
Piper Sandler Initiates Coverage of Perspective Therapeutics (CATX) with Overweight Recommendation - Nasdaq
Tue, 17 Feb 2026
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|